Log in

Relevant bibliographies by topics / Pd-103 / Journal articles

To see the other types of publications on this topic, follow the link: Pd-103.

Journal articles on the topic 'Pd-103'

Author: Grafiati

Published: 4 June 2021

Last updated: 6 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Pd-103.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Li, Zhong-Yong, Hui-Bo Gao, Xue-Song Deng, et al. "Preparation of 103 Pd brachytherapy seeds by electroless plating of 103 Pd onto carbon bars." Applied Radiation and Isotopes 103 (September 2015): 128–30. http://dx.doi.org/10.1016/j.apradiso.2015.05.020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Chaugule, Sonal S., and Paul T. Finger. "Regression Patterns of Iris Melanoma after Palladium-103 ( 103 Pd) Plaque Brachytherapy." Ophthalmology 124, no. 7 (2017): 1023–30. http://dx.doi.org/10.1016/j.ophtha.2017.02.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Butler, Wayne M., and Gregory S. Merrick. "Focal prostate brachytherapy with 103 Pd seeds." Physica Medica 32, no. 3 (2016): 459–64. http://dx.doi.org/10.1016/j.ejmp.2016.03.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Hall, Michael William, Jeffrey Horn, and Russell Fuhrer. "Allegheny General Hospital experience with LDR prostate brachytherapy comparing Pd-103 with I-125." Journal of Clinical Oncology 32, no. 4_suppl (2014): 274. http://dx.doi.org/10.1200/jco.2014.32.4_suppl.274.

Full text

Abstract:

274 Background: To report a retrospective review of a single institution’s experience treating patients with localized adenocarcinoma of the prostate with low-dose rate brachytherapy (LDR-BT) comparing clinical outcomes at 5 years of patients treated with Pd-103 vs. I-125. Methods: 332 hormone-naïve patients with localized adenocarcinoma of the prostate were treated with LDR-BT without androgen deprivation therapy (ADT) between 1998-2008 at Allegheny General Hospital. 300 patients had more than 12 months of follow-up and were included in the statistical analysis. 40 patients (13%) were treated

APA, Harvard, Vancouver, ISO, and other styles

5

Chin, Kimberly. "ULTRASONOGRAPHY OF UVEAL MELANOMAS AFTER PALLADIUM-103 (PD-103) OPHTHALMIC PLAQUE RADIATION THERAPY." Optometry and Vision Science 79, Supplement (2002): 96. http://dx.doi.org/10.1097/00006324-200212001-00182.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Trindade, Bruno Machado, Marília Tavares Christóvão, Daniela de Fátima Maia Trindade, Patrícia Lima Falcão, and Tarcisio Passos Ribeiro de Campos. "Dosimetria comparativa de braquiterapia de próstata com sementes de I-125 e Pd-103 via SISCODES/MCNP." Radiologia Brasileira 45, no. 5 (2012): 267–72. http://dx.doi.org/10.1590/s0100-39842012000500007.

Full text

Abstract:

OBJETIVO: O presente artigo visa apresentar um estudo dosimétrico comparativo de braquiterapia de próstata com sementes de I-125 e Pd-103. MATERIAIS E MÉTODOS: Um protocolo adotado para ambos os implantes com 148 sementes foi simulado em um fantoma tridimensional heterogêneo de pelve por meio dos códigos SISCODES/MCNP5. Histogramas dose-volume na próstata, bexiga e reto, índices de doses D10, D30, D90, D0,5cc, D2cc e D7cc, e representações de distribuição espacial de dose foram avaliados. RESULTADOS: A atividade inicial de cada semente de I-125, para que D90 seja equivalente à dose de prescriç

APA, Harvard, Vancouver, ISO, and other styles

7

Culberson, Wesley, Michael Mitch, Manik Aima, John Micka, and Larry DeWerd. "Calibration of a New Directional Pd-103 Source." Brachytherapy 15 (May 2016): S27. http://dx.doi.org/10.1016/j.brachy.2016.04.021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Peach, M. S., S. W. Dutta, K. Bauer-Nilsen, D. Campbell, B. Libby, and T. N. Showalter. "Palladium-103 (Pd-103) Prostate Cancer Brachytherapy: Long-Term Outcomes in over 700 Patients." International Journal of Radiation Oncology*Biology*Physics 102, no. 3 (2018): e133-e134. http://dx.doi.org/10.1016/j.ijrobp.2018.07.255.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Skouteris, V. M., N. N. Stone, R. G. Stock, and J. A. Cesaretti. "Dose Response Study of Pd-103 Prostate Seed Implantation." International Journal of Radiation Oncology*Biology*Physics 69, no. 3 (2007): S349—S350. http://dx.doi.org/10.1016/j.ijrobp.2007.07.1436.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Koumantaki, Yvoni, Stavros Sifakis, Georgios Dragatis, et al. "Microsatellite analysis provides efficient confirmation of fetal trophoblast isolation from maternal circulation." Prenatal Diagnosis 21, no. 7 (2001): 566–70. http://dx.doi.org/10.1002/pd.103.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Bidokhti, P. Saidi, M. Sadeghi, A. Shirazi, S. R. M. Mahdavi, and M. Mirzaii. "1388 poster DOSIMETRIC STUDY OF THE 103-PD EYE PLAQUE." Radiotherapy and Oncology 99 (May 2011): S516. http://dx.doi.org/10.1016/s0167-8140(11)71510-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Wallner, Kent, Gregory Merrick, Lawrence True, William Cavanagh, Colleen Simpson, and Wayne Butler. "1???125 Versus Pd-103 for Low-Risk Prostate Cancer." Cancer Journal 8, no. 1 (2002): 69–73. http://dx.doi.org/10.1097/00130404-200201000-00012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Herstein, Andrew, Kent Wallner, Gregory Merrick, et al. "I-125 Versus Pd-103 for Low-Risk Prostate Cancer." Cancer Journal 11, no. 5 (2005): 385–89. http://dx.doi.org/10.1097/00130404-200509000-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

ZABIHZADEH, MANSOUR, HADI REZAEE, ZAHRA SHAKARAMI, MOSTAFA FEGHHI, and MOHAMMAD HOSSEINI. "Dosimetric Characteristics of 103 Pd (Theragenices, Model 200) Brachytherapy Source." Biomedical and Pharmacology Journal 8, SEMAR (2015): 15–23. http://dx.doi.org/10.13005/bpj/550.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Ling, C. Clifton, William X. Li, and Lowell L. Anderson. "The relative biological effectiveness of I-125 and Pd-103." International Journal of Radiation Oncology*Biology*Physics 32, no. 2 (1995): 373–78. http://dx.doi.org/10.1016/0360-3016(95)00530-c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Rivard, Mark J., Joshua L. Reed, and Larry A. DeWerd. "Pd-103 Strings: A New Approach to Brachytherapy Source Design." Brachytherapy 13 (March 2014): S27. http://dx.doi.org/10.1016/j.brachy.2014.02.236.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Rivard, Mark J. "Dosimetry and Commissioning of a Directional Pd-103 Brachytherapy Source." Brachytherapy 15 (May 2016): S37—S38. http://dx.doi.org/10.1016/j.brachy.2016.04.038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Cohen, Gilad N., Xinjie Qiu, Abraham J. Wu, and Marco Zaider. "Considerations for the Clinical Use of CivaSheet Pd-103 Sources." Brachytherapy 15 (May 2016): S168. http://dx.doi.org/10.1016/j.brachy.2016.04.303.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Bostancic, C., G. S. Merrick, W. Butler, et al. "Prediction of PSA spikes by isotope and patient age following permanent prostate brachytherapy." Journal of Clinical Oncology 25, no. 18_suppl (2007): 15535. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.15535.

Full text

Abstract:

15535 Background: To evaluate prostate specific antigen (PSA) spikes (bounces) following permanent prostate brachytherapy in low-risk patients randomized to Pd-103 or I-125. Methods: The study population consisted of 164 prostate cancer patients who were part of a prospective randomized trial comparing Pd-103 with I-125 for low-risk disease. Sixty-one patients (37.2%) received short course cytoreductive androgen deprivation therapy (ADT). No patient received supplemental XRT. The median follow-up was 5.4 years. All patients were implanted at least 3 years prior to analysis. On average, 10.1 po

APA, Harvard, Vancouver, ISO, and other styles

20

Wu, Dao Xin, Ying Liu, and Zhong Liang Xiao. "Study on Kinetics of Electroless Plating Palladiumon on Ni-P Coatings." Advanced Materials Research 233-235 (May 2011): 2840–43. http://dx.doi.org/10.4028/www.scientific.net/amr.233-235.2840.

Full text

Abstract:

Single factor method was used to investigate the effects of the main technical parameters ,which was on the Pd deposition rate in electroless Pd plating process. The kinetic equation of palladium deposition was established. When the concentration of EDTA-2Na was less than 6g/L，V= 0.783 CA1.00784 CB0.15225 Cc-0.3373 CD0.29417 exp[10.76×103(T-298)/(298RT)] .When the concentration of EDTA-2Na was more than 6g/L ,V= 2.147CA1.00784 CB0.15225 Cc-0.3373 CD-0.33376 exp[10.76×103(T-298)/(298RT)] .

APA, Harvard, Vancouver, ISO, and other styles

21

Meigooni, Ali S., Hualin Zhang, Candace Perry, Sharifeh A. Dini, and Rafiq A. Koona. "Theoretical and experimental determination of dosimetric characteristics for brachyseed™ Pd-103, model Pd-1, source." Applied Radiation and Isotopes 58, no. 5 (2003): 533–41. http://dx.doi.org/10.1016/s0969-8043(02)00349-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Rahmat, Faisal Reza, Mondjo Mondjo, and Alexander Agung. "Calculation of Absorbed Dose Distribution for Breast Brachytherapy Simulation By CS-1 131Cs Seed and ADVANTAGETM 103Pd Seed Using Monte Carlo N Particle Extended Simulator." Indonesian Journal of Physics and Nuclear Applications 2, no. 2 (2017): 65. http://dx.doi.org/10.24246/ijpna.v2i2.65-74.

Full text

Abstract:

Simulation using Monte Carlo code has been conducted to determine the distribution of absorbed dose to the breast brachytherapy with <sup>131</sup>Cs and <sup>103</sup>Pd radionuclide sources. Simulations performed on stage I breast cancer with cancer diameter is 2 cm. Sources of radionuclides simulated in the form of seed is modeled with CS-1 which is made by IsoRay <sup>131</sup>Cs and seed ADVANTAGE<sup>TM</sup><sup>103</sup>Pd which is made by IsoAID, LLC. Seed was planted in breast cancer cells. Calculation of absorbed dose distr

APA, Harvard, Vancouver, ISO, and other styles

23

Aima, Manik, Joshua L. Reed, Larry A. DeWerd, and Wesley S. Culberson. "Air-kerma strength determination of a new directional 103 Pd source." Medical Physics 42, no. 12 (2015): 7144–52. http://dx.doi.org/10.1118/1.4935409.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Fontenla, Doracy P., Munir Ahmad, Sou-Tung Chiu-Tsao, and Lowell L. Anderson. "Diode dosimetry of 103 Pd model 200 seed in water phantom." Medical Physics 21, no. 6 (1994): 817–20. http://dx.doi.org/10.1118/1.597327.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Cohen, Gilad N., Abraham Wu, Karen Episcopia, Neil Taunk, Amandeep S. Taggar, and Antonio L. Damato. "Dose Specification and Source Ordering Nomogram for CivaSheet Pd-103 Sources." Brachytherapy 16, no. 3 (2017): S33. http://dx.doi.org/10.1016/j.brachy.2017.04.041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

He, Xiao Juan, Da Wei Qi, and Nan Hu. "Study on the Dose Parameters of ¹⁰³Pd Radioactive Seed." Advanced Materials Research 322 (August 2011): 239–42. http://dx.doi.org/10.4028/www.scientific.net/amr.322.239.

Full text

Abstract:

Abstract. The dose calculation parameters of 103Pd radioactive seed need to be determined strictly before clinical application for tumor implanted treatment. The radial dose function and the anisotropy factor are data analyzed and nonlinear fitted based on the value of dose parameters in American Association of Physicists in Medicine (AAPM) TG-43 and TG-43U1 by Cftool and SFTool toolbox in Matlab. Result was selected according to the optimum principle of fitting accuracy that is the coefficient of determination is close to 1 and gets the minimum value of the sum of square of deviations in fitt

APA, Harvard, Vancouver, ISO, and other styles

27

Mellenberg, David E., and Robert W. Kline. "Verification of manufacturer-supplied 125 I and 103 Pd air-kerma strengths." Medical Physics 22, no. 9 (1995): 1495–97. http://dx.doi.org/10.1118/1.597625.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Yang, Zhaoping, Simon E. Jackson, Louis J. Cabri, Pamela Wee, Henry P. Longerich, and Marcin Pawlak. "Quantitative determination of trace level (ng g−1) contents of rhodium and palladium in copper-rich minerals using LA-ICP-MS." Journal of Analytical Atomic Spectrometry 35, no. 3 (2020): 534–47. http://dx.doi.org/10.1039/c9ja00285e.

Full text

Abstract:

Measurement of ng g<sup>−1</sup> amounts of Rh and Pd in Cu-rich minerals by LA single quadrupole and tandem MS ICP-MS, using He collision gas and (NH<sub>3</sub>)/He (10%/90%) reaction gas, respectively, to attenuate CuAr interferences on <sup>103</sup>Rh and <sup>105</sup>Pd.

APA, Harvard, Vancouver, ISO, and other styles

29

Chan, Gordon H., and William V. Prestwich. "Monte Carlo investigation of the dosimetric properties of the new 103PdBrachySeed™Pd-103 Model Pd-1 source." Medical Physics 29, no. 9 (2002): 1984–90. http://dx.doi.org/10.1118/1.1500405.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Devhare, Pradip, Revati Patil, Dadasaheb B. Akolkar, et al. "PD-L1 profiling of circulating tumor cells for immune checkpoint inhibitor therapy in gastroesophageal cancers." Journal of Clinical Oncology 38, no. 5_suppl (2020): 29. http://dx.doi.org/10.1200/jco.2020.38.5_suppl.29.

Full text

Abstract:

29 Background: Selection of Immune Checkpoint Inhibitor (ICI) therapies in Gastroesophageal cancers are based on IHC based detection of PD-L1 expression in tumor tissue. Invasive biopsy to obtain tumor tissue for IHC is associated with procedural risks, sequelae and expenses. Prior efforts at PD-L1 profiling of Circulating Tumor Cells (CTCs) have been constrained by low CTC yields. We employed a novel approach for harvesting sufficient CTCs from Gastroesophageal cancers that permit PD-L1 profiling by Immunocytochemistry (ICC). Methods: 15 ml peripheral blood was collected from 106 patients amo

APA, Harvard, Vancouver, ISO, and other styles

31

Falloon, Peter G. "Survey of California Asparagus for Asparagus Virus I, Asparagus Virus II, and Tobacco Streak Virus." Plant Disease 70, no. 2 (1986): 103. http://dx.doi.org/10.1094/pd-70-103.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Packard, Matthew, Vladimir Valakh, and Russell Fuhrer. "Implant R100 Predicts Rectal Bleeding in Prostate Cancer Patients Treated with IG-IMRT to 45 Gy and Pd-103 Implant." Journal of Radiotherapy 2014 (February 4, 2014): 1–6. http://dx.doi.org/10.1155/2014/130652.

Full text

Abstract:

Purpose. To define factors associated with rectal bleeding in patients treated with IG-IMRT followed by Pd-103 seed implant. Methods and Materials. We retrospectively reviewed 61 prostate adenocarcinoma patients from 2002 to 2008. The majority (85.2%) were of NCCN intermediate risk category. All received IG-IMRT to the prostate and seminal vesicles followed by Pd-103 implant delivering a mean D90 of 100.7 Gy. Six patients received 45 Gy to the pelvic nodes and 10 received androgen deprivation. Results. Ten patients (16.4%) developed rectal bleeding: 4 were CTCAE v.3 grade 1, 5 were grade 2, an

APA, Harvard, Vancouver, ISO, and other styles

33

Matsumoto, Mitsuru, Makoto Itoh, Shigenobu Funahashi, and Hideo D. Takagi. "Article." Canadian Journal of Chemistry 77, no. 10 (1999): 1638–47. http://dx.doi.org/10.1139/v99-190.

Full text

Abstract:

The oxidation reactions of Pd(ttcn)22+, Pt(ttcn)22+, and Au(ttcn)22+ (ttcn = 1,4,7-trithiacyclononane) complexes by a typical outer-sphere oxidizing reagent, Ni(tacn)23+ (tacn = 1,4,7-triazacyclononane), were studied in aqueous acidic solution and in acetonitrile. The rate constants corresponding to the oxidation and reduction reactions were isolated for Pd(ttcn)23+/2+ and Au(ttcn)23+/2+ couples in both media. The electron exchange rate constants (kex) for Pd(ttcn)23+/2+, Pt(ttcn)23+/2+, and Au(ttcn)23+/2+ couples at 25°C were estimated as 1.7 × 103, 59, 3.9 × 104 mol-1 dm3 s-1 in aqueous solu

APA, Harvard, Vancouver, ISO, and other styles

34

Saidi, Pooneh, Mahdi Sadeghi, Alireza Shirazi, Seied Rabie Mahdavi, and Mohammad Mirzaii. "Dosimetry analysis of two new design ¹⁰³Pd interstitial brachytherapy sources." International Journal of Low Radiation 8, no. 5/6 (2011): 363. http://dx.doi.org/10.1504/ijlr.2011.047177.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Nath, Ravinder, Ali S. Meigooni, Philip Muench, and Anthony Melillo. "Anisotropy functions for 103 Pd, 125 I, and 192 Ir interstitial brachytherapy sources." Medical Physics 20, no. 5 (1993): 1465–73. http://dx.doi.org/10.1118/1.597110.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Rivard, Mark J., Markus M. Fitzek, Paul E. Daniel, and Jeffrey S. Heier. "Clinical results of HDR Pd-103 brachytherapy for wet age-related macular degeneration." Brachytherapy 5, no. 2 (2006): 98. http://dx.doi.org/10.1016/j.brachy.2006.03.070.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Anderson, Danielle, Deidre Batchelar, Michelle Hilts, Marie-Pierre Milette, and Juanita Crook. "A Quantitative Evaluation of Pd-103 Permanent Breast Seed Implant Mark-Up Procedure." Brachytherapy 16, no. 3 (2017): S53. http://dx.doi.org/10.1016/j.brachy.2017.04.086.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Phan, Alexandria T., Arvind Dasari, Nilani Liyanage, David Cox, Susan Pitman Lowenthal, and Edward M. Wolin. "Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs)." Journal of Clinical Oncology 34, no. 4_suppl (2016): 434. http://dx.doi.org/10.1200/jco.2016.34.4_suppl.434.

Full text

Abstract:

434 Background: In the CLARINET study, significant improvement in progression-free survival (primary endpoint) was reported in patients (pts) treated with lanreotide depot (LAN), a long-acting somatostatin analog, for moderately- or well-differentiated, nonfunctioning, locally advanced or metastatic GEP-NETs. A favorable safety profile was also observed. This retrospective analysis presents tumor response from CLARINET. Methods: Pts were randomized to LAN 120 mg (n=101) or PBO (n=103) once every 28 days for 96 weeks. Tumor response was evaluated centrally using RECIST version 1.0. Pts’ tumors

APA, Harvard, Vancouver, ISO, and other styles

39

Booher, Jacquelyn G., Peter Domenig, and Paul J. Chuba. "Isotope selection and PSA failure in prostate seed implant: Experience with CS-131 in a community hospital system." Journal of Clinical Oncology 38, no. 6_suppl (2020): 375. http://dx.doi.org/10.1200/jco.2020.38.6_suppl.375.

Full text

Abstract:

375 Background: A recent large single institutional study reported excellent long-term biochemical control and survival for Cs-131 prostate implant. This isotope has short half-life (9.7 days) with clinical advantages including shorter duration of symptoms. We previously showed Cs-131 dosimetry to be quantitatively similar to I-125 with improved homogeneity (mean percent V150 36% for I-125 versus 27% for Cs-131 (p < 0.0001). Our objective was to evaluate PSA failure rates and dosimetric outcomes in a multi-institutional community based setting. Methods: Within an IRB approved retrospective

APA, Harvard, Vancouver, ISO, and other styles

40

Terakedis, B. E., C. Bergstrom, M. Lynn, et al. "Visual Acuity Outcomes with Palladium 103 (Pd-103) vs. Iodine 125 (I-125) Plaque Treatment for Choroidal Melanoma: The Emory University Experience." International Journal of Radiation Oncology*Biology*Physics 75, no. 3 (2009): S229—S230. http://dx.doi.org/10.1016/j.ijrobp.2009.07.529.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

BIEDERMAN, JOSEPH, CARTER PETTY, DINA R. HIRSHFELD-BECKER, et al. "A controlled longitudinal 5-year follow-up study of children at high and low risk for panic disorder and major depression." Psychological Medicine 36, no. 8 (2006): 1141–52. http://dx.doi.org/10.1017/s0033291706007781.

Full text

Abstract:

Background. To evaluate the longitudinal course of psychiatric disorders in children of parents with panic disorder (PD) and major depression (MD) as they transition through the period of risk from childhood into adolescence.Method. Over a 5-year follow-up, we compared psychiatric disorders in four groups of children: (1) offspring of parents with PD plus MD (n=136); (2) offspring of parents with PD without MD (n=27); (3) offspring of parents with MD but without PD (n=53); and (4) offspring of non-PD non-MD parents (n=103).Results. Parental PD was significantly associated with increased risk f

APA, Harvard, Vancouver, ISO, and other styles

42

Wang, Xing Ye, Bing Jun Shen, Li Hong Jin, Xin Le Zhao, and Jian Tian. "Excess Heat Triggering by 488 nm Laser in a D/Pd Gas-Loading System." Advanced Materials Research 834-836 (October 2013): 1182–85. http://dx.doi.org/10.4028/www.scientific.net/amr.834-836.1182.

Full text

Abstract:

A beam of Argon ion laser (λ = 488 nm and P = 40 mW) was used to irradiate some palladium deuterides with different deuteron loading ratios in a D/Pd gas-loading system (19 different loading ratios ranging from 0 to 0.77). The results showed that there was a maximum excess heat of about 287 J within an hour in the system when the loading ratio was about 0.65. This corresponds to 2.6×103 eV/atom D or 1.7 ×103eV/atom Pd. The results indicate that the proper ratio in the Pd lattice matching a suitable triggering power may be the key factor to excess heat production.

APA, Harvard, Vancouver, ISO, and other styles

43

Hu, Man, Song Xue, Jinming Yu, Bingjie Fan, Ji Ma та Li Xie. "Hypoxia-inducible factor 1α in regulation of programmed death: Ligand 1 in glioma under hypoxia microenvironment." Journal of Clinical Oncology 35, № 7_suppl (2017): 103. http://dx.doi.org/10.1200/jco.2017.35.7_suppl.103.

Full text

Abstract:

103 Background: Glioma is a highly lethal tumor that is known for its immune inhibitory capabilities. Despite great progress in treatment modalities, the median survival time of high-grade gliomas patients is only about 11.1 months. Gliomas are aberrantly expressed programmed death–ligand 1 (PD-L1) which results in tumor-induced immune suppression. Hypoxia is well known to induce aggressiveness, promotes tumor progression and resistance to chemotherapy and radiotherapy. Recently, studies have indicated that hypoxia play a prominent role in tumor immune escape. The aim of the study was to explo

APA, Harvard, Vancouver, ISO, and other styles

44

Seltzer, S. M., P. J. Lamperti, R. Loevinger, M. G. Mitch, J. T. Weaver, and B. M. Coursey. "New national air-kerma-strength standards for I-125 and Pd-103 brachytherapy seeds." Journal of Research of the National Institute of Standards and Technology 108, no. 5 (2003): 337. http://dx.doi.org/10.6028/jres.108.030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Saidi, P., M. Sadeghi, and C. Tenreiro. "27 BRACHYTHERAPY DOSIMETRY FOR COMS EYE PLAQUE WITH TWO VARIOUS 103-PD SEED MODELS." Radiotherapy and Oncology 102 (March 2012): S7. http://dx.doi.org/10.1016/s0167-8140(12)70014-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Meigooni, Ali S., Sharifeh A. Dini, Shahid B. Awan, Kai Dou, and Rafiq A. Koona. "Theoretical and experimental determination of dosimetric characteristics for ADVANTAGE™ Pd-103 brachytherapy source." Applied Radiation and Isotopes 64, no. 8 (2006): 881–87. http://dx.doi.org/10.1016/j.apradiso.2006.03.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Rivard, MJ. "SU-F-BRA-06: Dose Distributions for the CivaSheet Pd-103 Directional Brachytherapy Device." Medical Physics 42, no. 6Part26 (2015): 3534–35. http://dx.doi.org/10.1118/1.4925217.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Napolitano, M., and W. Butler. "SU-FF-T-40: Monte Carlo Calculation of Pd-103 Prostate Implant Treatment Plan." Medical Physics 32, no. 6Part7 (2005): 1958. http://dx.doi.org/10.1118/1.1997711.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Serrano, N. A., H. T. Pham, S. Narayanan, and K. R. Badiozamani. "Does Pd-103 Prostate Brachytherapy Lead to High Rates of Urinary Retention and Morbidity?" International Journal of Radiation Oncology*Biology*Physics 87, no. 2 (2013): S346. http://dx.doi.org/10.1016/j.ijrobp.2013.06.910.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Rivard, Mark J. "Influence of Implant Curvature for Improved Post-Surgical Dosimetry of Directional 103 Pd Sources." Brachytherapy 17, no. 4 (2018): S30—S31. http://dx.doi.org/10.1016/j.brachy.2018.04.040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!